Your browser doesn't support javascript.
loading
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.
Herling, Carmen D; Cymbalista, Florence; Groß-Ophoff-Müller, Carolin; Bahlo, Jasmin; Robrecht, Sandra; Langerbeins, Petra; Fink, Anna-Maria; Al-Sawaf, Othman; Busch, Raymonde; Porcher, Raphael; Cazin, Bruno; Dreyfus, Brigitte; Ibach, Stefan; Leprêtre, Stéphane; Fischer, Kirsten; Kaiser, Florian; Eichhorst, Barbara; Wentner, Clemens-Martin; Hoechstetter, Manuela A; Döhner, Hartmut; Leblond, Veronique; Kneba, Michael; Letestu, Remi; Böttcher, Sebastian; Stilgenbauer, Stephan; Hallek, Michael; Levy, Vincent.
Afiliação
  • Herling CD; Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany. carmen.herling@uk-koeln.de.
  • Cymbalista F; Hopital Avicenne, Assistance Publique-Hopitaux de Paris (AP-HP), Service d'Hematologie Biologique, Bobigny, France.
  • Groß-Ophoff-Müller C; Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
  • Bahlo J; Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
  • Robrecht S; Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
  • Langerbeins P; Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
  • Fink AM; Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
  • Al-Sawaf O; Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
  • Busch R; Institute for Medical Statistics and Epidemiology, Technical University, Munich, Germany.
  • Porcher R; Center of Clinical Epidemiology, Hopital Hotel-Dieu, Paris, France.
  • Cazin B; Service de Maladies du Sang, CHU Claude Huriez, Lille Cedex, France.
  • Dreyfus B; Service d'Hematologie, CHU Poitiers, Poitiers, France.
  • Ibach S; WiSP Wissenschaftlicher Service Pharma GmbH, Langenfeld, Germany.
  • Leprêtre S; Inserm Unit U1245 and Department of Hematology, Cancer Centre Henri Becquerel and Normandie University Rouen, Rouen, France.
  • Fischer K; Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
  • Kaiser F; Day Clinic Hematology Oncology Palliative Care, Landshut, Germany.
  • Eichhorst B; Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
  • Wentner CM; Department of Hematology Oncology, Immunology, Palliative Medicine, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany.
  • Hoechstetter MA; Department of Hematology Oncology, Immunology, Palliative Medicine, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany.
  • Döhner H; Department of Internal Medicine III, University of Ulm, Ulm, Germany.
  • Leblond V; Department of Haematology, Hopital de la Pitie-Salpetriere, Paris, France.
  • Kneba M; Second Department of Medicine, University of Schleswig-Holstein, Kiel, Germany.
  • Letestu R; Hopital Avicenne, Assistance Publique-Hopitaux de Paris (AP-HP), Service d'Hematologie Biologique, Bobigny, France.
  • Böttcher S; Second Department of Medicine, University of Schleswig-Holstein, Kiel, Germany.
  • Stilgenbauer S; Department of Hematology, Oncology and Palliative Medicine, Center for Internal Medicine, University of Rostock, Rostock, Germany.
  • Hallek M; Department of Internal Medicine III, University of Ulm, Ulm, Germany.
  • Levy V; Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Leukemia ; 34(8): 2038-2050, 2020 08.
Article em En | MEDLINE | ID: mdl-32071431
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article